Natriuretic Peptides as Therapy in Cardiac Ischaemia/Reperfusion

Danish Medical Journal

Volumn 59, Issue 6, 2012, Pages

  Kousholt, Birgitte Saima ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATRIAL NATRIURETIC FACTOR; BETA ACTIN; BICARBONATE; BRAIN NATRIURETIC PEPTIDE; CASPASE; CHOLESTEROL; FATTY ACID; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE (NADP); GLYCEROL; HEPARIN; LACTIC ACID; MESSENGER RNA; NATRIURETIC PEPTIDE TYPE C; POTASSIUM; TRIACYLGLYCEROL; TROPONIN T; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BLOOD OXYGEN TENSION; CORE TEMPERATURE; DIURESIS; GENE EXPRESSION; HEART ARRHYTHMIA; HEART INFARCTION SIZE; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART OUTPUT; HEART RATE; HEMODYNAMICS; HUMAN; INTRACELLULAR SIGNALING; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID STORAGE; LUNG ARTERY PRESSURE; MEAN ARTERIAL PRESSURE; NONHUMAN; PH; RADIOIMMUNOASSAY; REAL TIME POLYMERASE CHAIN REACTION; RISK; RNA EXTRACTION; THIN LAYER CHROMATOGRAPHY;

EID: 84873265645     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (157)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 2011 Feb 1;123(4):e18-e209.
2. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007 Jun 7;356(23):2388-2398.
3. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001 Nov 27;104(22):2746-2753.
4. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001 Dec 4;104(23):2855-2864.
5. White HD, Chew DP. Acute myocardial infarction. Lancet 2008 Aug 16;372(9638):570-584.
6. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/ reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007 Dec;59(4):418-458.
7. Simoons ML, Boersma E, Maas AC, Deckers JW. Management of myocardial infarction: the proper priorities. Eur Heart J 1997 Jun;18(6):896-899.
8. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocar dial infarction: a quantitative review of 23 randomised trials. Lancet 2003 Jan 4;361(9351):13-20.
9. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 2007 Nov;152(6):855-869.
10. Saito Y. Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol 2010 11;56(3):262-270.
11. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981 Jan 5;28(1):89-94.
12. Flynn TG, de Bold ML, de Bold AJ. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 1983 Dec 28;117(3):859-865.
13. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988 Mar 3;332(6159):78-81.
14. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990 Apr 30;168(2):863-870.
15. Sudoh T, Minamino N, Kangawa K, Matsuo H. Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain. Biochem Biophys Res Commun 1988 Sep 15;155(2):726-732.
16. Maekawa K, Sudoh T, Furusawa M, Minamino N, Kangawa K, Ohkubo H, et al. Cloning and sequence analysis of cDNA encoding a precursor for porcine brain natriuretic peptide. Biochem Biophys Res Commun 1988 Nov 30;157(1):410-416.
17. Saito Y, Nakao K, Itoh H, Yamada T, Mukoyama M, Arai H, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989 Jan 31;158(2):360-368.
18. Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988 Sep 1;66(17):752-759.
19. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 1992 Jul 15;267(20):13928-13932.
20. Baxter GF. The natriuretic peptides. Basic Res Cardiol 2004 Mar;99(2):71-75.
21. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004 Sep;50(9):1503-1510.
22. Lippert S, Goetze JP. C-type natriuretic-derived peptides as biomarkers in human disease. Biomark Med 2010 Aug;4(4):631-639.
23. Seilhamer JJ, Arfsten A, Miller JA, Lundquist P, Scarborough RM, Lewicki JA, et al. Human and canine gene homologs of porcine brain natriuretic peptide. Biochem Biophys Res Commun 1989 Dec 15;165(2):650-658.
24. Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for rat brain natriuretic peptide. Biochem Biophys Res Commun 1989 Mar 31;159(3):1420-1426.
25. Ogawa Y, Itoh H, Tamura N, Suga S, Yoshimasa T, Uehira M, et al. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest 1994 May;93(5):1911-1921.
26. Christoffersen C, Goetze JP, Bartels ED, Larsen MO, Ribel U, Rehfeld JF, et al. Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. Hypertension 2002 Jul;40(1):54-60.
27. Mantymaa P, Vuolteenaho O, Marttila M, Ruskoaho H. Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology 1993 Sep;133(3):1470-1473.
28. Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004 Dec;18(15):1928-1930.
29. Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995 Sep 15;92(6):1558-1564.
30. Nielsen SJ, Gotze JP, Jensen HL, Rehfeld JF. ProCNP and CNP are expressed primarily in male genital organs. Regul Pept 2008 Feb 7;146(1-3):204-212.
31. Chun TH, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T, et al. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension 1997 Jun;29(6):1296-1302.
32. Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system". J Clin Invest 1992 Sep;90(3):1145-1149.
33. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986 Nov;78(5):1362-1374.
34. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991 Apr;87(4):1402-1412.
35. Goetze JP, Rehfeld JF, Videbaek R, Friis-Hansen L, Kastrup J. B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts. Eur J Heart Fail 2005 Jan;7(1):69-74.
36. Langenickel T, Buttgereit J, Pagel I, Dietz R, Willenbrock R, Bader M. Forced homodimerization by site-directed mutagenesis alters guanylyl cyclase activity of natriuretic peptide receptor B. Hypertension 2004 Feb;43(2):460-465.
37. Wilson EM, Chinkers M. Identification of sequences mediating guanylyl cyclase dimerization. Biochemistry 1995 Apr 11;34(14):4696-4701.
38. Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR. Distinct and specific functions of cGMPdependent protein kinases. Trends Biochem Sci 1997 Aug;22(8):307-312.
39. Kaupp UB, Seifert R. Cyclic nucleotide-gated ion channels. Physiol Rev 2002 Jul;82(3):769-824.
40. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003 Sep;64(3):533-546.
41. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M, et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A 1999 Jun 22;96(13):7403-7408.
42. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endotheliumderived C-type natriuretic peptide. Circulation 2004 Sep 7;110(10):1231-1235.
43. Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992 Jan;130(1):229-239.
44. Levin ER. Natriuretic peptide C-receptor: more than a clearance receptor. Am J Physiol 1993 Apr;264(4 Pt 1):E483-9.
45. Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 1996 Oct;19(9):581-585.
46. Wilcox JN, Augustine A, Goeddel DV, Lowe DG. Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol 1991 Jul;11(7):3454-3462.
47. Del Ry S, Cabiati M, Lionetti V, Simioniuc A, Caselli C, Prescimone T, et al. Asymmetrical myocardial expression of natriuretic peptides in pacing-induced heart failure. Peptides 2009 Jun 21.
48. Ohyama Y, Miyamoto K, Morishita Y, Matsuda Y, Saito Y, Minamino N, et al. Stable expression of natriuretic peptide receptors: effects of HS-142-1, a non-peptide ANP antagonist. Biochem Biophys Res Commun 1992 Nov 30;189(1):336-342.
49. Vogel MW, Chen HH. Novel natriuretic peptides: new compounds and new approaches. Curr Heart Fail Rep 2011 Mar;8(1):22-27.
50. Lee CY, Lieu H, Burnett JC, Jr. Designer natriuretic peptides. J Investig Med 2009 Jan;57(1):18-21.
51. Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, et al. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci U S A 2009 Jul 7;106(27):11282-11287.
52. Kilic A, Rajapurohitam V, Sandberg SM, Zeidan A, Hunter JC, Said Faruq N, et al. A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway. Cardiovasc Res 2010 Dec 1;88(3):434-442.
53. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC, Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008 Jul 1;52(1):60-68.
54. Schirger JA, Heublein DM, Chen HH, Lisy O, Jougasaki M, Wennberg PW, et al. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc 1999 Feb;74(2):126-130.
55. Dickey DM, Burnett JC, Jr, Potter LR. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008 Dec 12;283(50):35003-35009.
56. Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009 Jun;49(6):668-673.
57. Dickey DM, Potter LR. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J Mol Cell Cardiol 2011 Jul;51(1):67-71.
58. Shah SJ, Michaels AD. Acute effects of intravenous nesiritide on cardiac contractility in heart failure. J Card Fail 2010 Sep;16(9):720-727.
59. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 2005 Jun;90(6):3622-3628.
60. Addisu A, Gower WR, Jr, Landon CS, Dietz JR. B-type natriuretic peptide decreases gastric emptying and absorption. Exp Biol Med (Maywood) 2008 Apr;233(4):475-482.
61. Casserly BP, Sears EH, Gartman EJ. The role of natriuretic peptides in inflammation and immunity. Recent Pat Inflamm Allergy Drug Discov 2010 Jun;4(2):90-104.
62. Burnett JC, Jr, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984 Nov;247(5 Pt 2):F863-6.
63. Richards AM, McDonald D, Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, et al. Atrial natriuretic hormone has biological effects in man at physiological plasma concentrations. J Clin Endocrinol Metab 1988 Dec;67(6):1134-1139.
64. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993 Jan;76(1):91-96.
65. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000 Apr 11;97(8):4239-4244.
66. Wang D, Oparil S, Feng JA, Li P, Perry G, Chen LB, et al. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptidenull mouse. Hypertension 2003 Jul;42(1):88-95.
67. John SW, Veress AT, Honrath U, Chong CK, Peng L, Smithies O, et al. Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am J Physiol 1996 Jul;271(1 Pt 2):R109-14.
68. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 1990 Sep;16(3):301-307.
69. Oliver PM, John SW, Purdy KE, Kim R, Maeda N, Goy MF, et al. Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-dependent manner. Proc Natl Acad Sci U S A 1998 Mar 3;95(5):2547-2551.
70. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995 Nov 2;378(6552):65-68.
71. Kilic A, Velic A, De Windt LJ, Fabritz L, Voss M, Mitko D, et al. Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice. Circulation 2005 Oct 11;112(15):2307-2317.
72. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bubikat A, Begrow F, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003 May;111(9):1399-1407.
73. Holtwick R, Gotthardt M, Skryabin B, Steinmetz M, Potthast R, Zetsche B, et al. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci U S A 2002 May 14;99(10):7142-7147.
74. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, et al. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 2005 Jun;115(6):1666-1674.
75. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009 Jun 2;53(22):2070-2077.
76. Bartels ED, Nielsen JM, Bisgaard LS, Goetze JP, Nielsen LB. Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice. Endocrinology 2010 Nov;151(11):5218-5225.
77. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004 Feb 10;109(5):594-600.
78. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 2000 Jul;14(10):1345-1351.
79. Sengenes C, Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M, et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormonesensitive lipase phosphorylation in human adipocytes. J Biol Chem 2003 Dec 5;278(49):48617-48626.
80. Moro C, Pillard F, de Glisezinski I, Crampes F, Thalamas C, Harant I, et al. Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in humans. Am J Physiol Regul Integr Comp Physiol 2007 Aug;293(2):R612-7.
81. Moro C, Polak J, Hejnova J, Klimcakova E, Crampes F, Stich V, et al. Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise. Am J Physiol Endocrinol Metab 2006 May;290(5):E864-9.
82. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994 Sep 23;269(38):23757-23763.
83. Huss JM, Levy FH, Kelly DP. Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid X receptor gene regulatory pathway in cardiac myocytes: a mechanism for O2-dependent modulation of mitochondrial fatty acid oxidation. J Biol Chem 2001 Jul 20;276(29):27605-27612.
84. van der Vusse GJ, Roemen TH, Prinzen FW, Coumans WA, Reneman RS. Uptake and tissue content of fatty acids in dog myocardium under normoxic and ischemic conditions. Circ Res 1982 Apr;50(4):538-546.
85. Giricz Z, Gorbe A, Pipis J, Burley DS, Ferdinandy P, Baxter GF. Hyperlipidaemia induced by a high-cholesterol diet leads to the deterioration of guanosine-3',5'-cyclic monophosphate/ protein kinase G-dependent cardioprotection in rats. Br J Pharmacol 2009 Nov;158(6):1495-1502.
86. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986 Nov;74(5):1124-1136.
87. Burley DS, Baxter GF. Pharmacological targets revealed by myocardial postconditioning. Curr Opin Pharmacol 2009 Apr;9(2):177-188.
88. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004 Feb 15;61(3):448-460.
89. Zhao ZQ, Nakamura M, Wang NP, Wilcox JN, Shearer S, Ronson RS, et al. Reperfusion induces myocardial apoptotic cell death. Cardiovasc Res 2000 Feb;45(3):651-660.
90. Borutaite V, Jekabsone A, Morkuniene R, Brown GC. Inhibition of mitochondrial permeability transition prevents mitochondrial dysfunction, cytochrome c release and apoptosis induced by heart ischemia. J Mol Cell Cardiol 2003 Apr;35(4):357-366.
91. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003 Apr;35(4):339-341.
92. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008 Apr;88(2):581-609.
93. Zhao ZQ, Velez DA, Wang NP, Hewan-Lowe KO, Nakamura M, Guyton RA, et al. Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis 2001 Aug;6(4):279-290.
94. JENNINGS RB, SOMMERS HM, SMYTH GA, FLACK HA, LINN H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960 Jul;70:68-78.
95. Ganz W. Direct Demonstration in Dogs of the Absence of Lethal Reperfusion Injury. J Thromb Thrombolysis 1997 Jan;4(1):105-107.
96. Farb A, Kolodgie FD, Jenkins M, Virmani R. Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. J Am Coll Cardiol 1993 Apr;21(5):1245-1253.
97. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998 May;38(2):291-300.
98. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999 Apr;79(2):609-634.
99. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2006 Sep;3(9):499-506.
100. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms and prevention. J Mol Cell Cardiol 1984 Jun;16(6):497-518.
101. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007 Sep 13;357(11):1121-1135.
102. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006 May 1;70(2):181-190.
103. Lemasters JJ, Bond JM, Chacon E, Harper IS, Kaplan SH, Ohata H, et al. The pH paradox in ischemia-reperfusion injury to cardiac myocytes. EXS 1996;76:99-114.
104. Crompton M, Costi A, Hayat L. Evidence for the presence of a reversible Ca2+-dependent pore activated by oxidative stress in heart mitochondria. Biochem J 1987 Aug 1;245(3):915-918.
105. Halestrap AP. A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans 2010 Aug;38(4):841-860.
106. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007 Dec;12(3-4):217-234.
107. SODI-PALLARES D, TESTELLI MR, FISHLEDER BL, BISTENI A, MEDRANO GA, FRIEDLAND C, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol 1962 Feb;9:166-181.
108. Sack MN, Yellon DM. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 2003 Apr 16;41(8):1404-1407.
109. Burley DS, Hamid SA, Baxter GF. Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev 2007 Dec;12(3-4):279-291.
110. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008 Feb 7;146(1-3):243-249.
111. Burley DS, Baxter GF. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol 2007 Nov;102(6):529-541.
112. D'Souza SP, Yellon DM, Martin C, Schulz R, Heusch G, Onody A, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003 May;284(5):H1592-600.
113. Inserte J, Garcia-Dorado D, Agullo L, Paniagua A, Soler-Soler J. Urodilatin limits acute reperfusion injury in the isolated rat heart. Cardiovasc Res 2000 Jan 14;45(2):351-359.
114. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007 Oct 27;370(9597):1483-1493.
115. Padilla F, Garcia-Dorado D, Agullo L, Barrabes JA, Inserte J, Escalona N, et al. Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res 2001 Aug 15;51(3):592-600.
116. McKie PM, Sangaralingham SJ, Burnett JC, Jr. CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep 2010 Sep;7(3):93-99.
117. Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006 Jul;101(4):311-318.
118. Gorbe A, Giricz Z, Szunyog A, Csont T, Burley DS, Baxter GF, et al. Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Res Cardiol 2010 Sep;105(5):643-650.
119. Hempel A, Friedrich M, Schluter KD, Forssmann WG, Kuhn M, Piper HM. ANP protects against reoxygenationinduced hypercontracture in adult cardiomyocytes. Am J Physiol 1997 Jul;273(1 Pt 2):H244-9.
120. Abdallah Y, Gkatzoflia A, Pieper H, Zoga E, Walther S, Kasseckert S, et al. Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury. Cardiovasc Res 2005 Apr 1;66(1):123-131.
121. Klaiber M, Dankworth B, Kruse M, Hartmann M, Nikolaev VO, Yang RB, et al. A cardiac pathway of cyclic GMP-independent signaling of guanylyl cyclase A, the receptor for atrial natriuretic peptide. Proc Natl Acad Sci U S A 2011 Oct 25.
122. Hillock RJ, Frampton CM, Yandle TG, Troughton RW, Lainchbury JG, Richards AM. B-type natriuretic peptide infusions in acute myocardial infarction. Heart 2008 May;94(5):617-622.
123. Heusch G, Skyschally A, Schulz R. The in-situ pig heart with regional ischemia/reperfusion-ready for translation. J Mol Cell Cardiol 2011 Jun;50(6):951-963.
124. Duncker DJ, Klassen CL, Ishibashi Y, Herrlinger SH, Pavek TJ, Bache RJ. Effect of temperature on myocardial infarction in swine. Am J Physiol 1996 Apr;270(4 Pt 2):H1189-99.
125. Maeng M, Mortensen UM, Kristensen J, Kristiansen SB, Andersen HR. Hypothermia during reperfusion does not reduce myocardial infarct size in pigs. Basic Res Cardiol 2006 Jan;101(1):61-68.
126. Schwartz LM, Verbinski SG, Vander Heide RS, Reimer KA. Epicardial temperature is a major predictor of myocardial infarct size in dogs. J Mol Cell Cardiol 1997 Jun;29(6):1577-1583.
127. Horneffer PJ, Healy B, Gott VL, Gardner TJ. The rapid evolution of a myocardial infarction in an end-artery coronary preparation. Circulation 1987 Nov;76(5 Pt 2):V39-42.
128. Wittnich C, Peniston C, Ianuzzo D, Abel JG, Salerno TA. Relative vulnerability of neonatal and adult hearts to ischemic injury. Circulation 1987 Nov;76(5 Pt 2):V156-60.
129. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011 Jul;301(1):H12-20.
130. Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 2010 May 11;121(18):2012-2022.
131. Larsen JR, Aagaard SR, Hasenkam JM, Sloth E. Preocclusion ischaemia, not sevoflurane, successfully preconditions the myocardium against further damage in porcine in vivo hearts. Acta Anaesthesiol Scand 2007 Apr;51(4):402-409.
132. Claycomb WC, Lanson NA, Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 1998 Mar 17;95(6):2979-2984.
133. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, et al. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981 May;101(5):593-600.
134. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010 Sep 14;122(11 Suppl):S124-31.
135. Hunter I, Rehfeld JF, Goetze JP. Measurement of the total proANP product in mammals by processing independent analysis. J Immunol Methods 2011 Jul 29;370(1-2):104-110.
136. Rehfeld JF, Goetze JP. The posttranslational phase of gene expression: new possibilities in molecular diagnosis. Curr Mol Med 2003 Feb;3(1):25-38.
137. Nielsen LB, Bartels ED, Bollano E. Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice. J Biol Chem 2002 Jul 26;277(30):27014-27020.
138. Casals G, Ros J, Sionis A, Davidson MM, Morales-Ruiz M, Jimenez W. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol 2009 Aug;297(2):H550-5.
139. Nakanishi M, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, et al. Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension 2005 Aug;46(2):441-447.
140. Wang TN, Ge YK, Li JY, Zeng XH, Zheng XX. B-type natriuretic peptide enhances mild hypoxia-induced apoptotic cell death in cardiomyocytes. Biol Pharm Bull 2007 Jun;30(6):1084-1090.
141. Shizukuda Y, Mallet RT, Lee SC, Downey HF. Hypoxic preconditioning of ischaemic canine myocardium. Cardiovasc Res 1992 May;26(5):534-542.
142. Kato T, Muraski J, Chen Y, Tsujita Y, Wall J, Glembotski CC, et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 2005 Oct;115(10):2716-2730.
143. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009;(191)(191):341-366.
144. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000 Feb 15;97(4):1784-1789.
145. Liedtke AJ, Nellis S, Neely JR. Effects of excess free fatty acids on mechanical and metabolic function in normal and ischemic myocardium in swine. Circ Res 1978 Oct;43(4):652-661.
146. Perman JC, Bostrom P, Lindbom M, Lidberg U, St. Ahlman M, Hagg D, et al. The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction. J Clin Invest 2011 Jul 1;121(7):2625-2640.
147. Xiangdong L, Yuanwu L, Hua Z, Liming R, Qiuyan L, Ning L. Animal models for the atherosclerosis research: a review. Protein Cell 2011 Mar;2(3):189-201.
148. Goldlust EJ, Paczynski RP, He YY, Hsu CY, Goldberg MP. Automated measurement of infarct size with scanned images of triphenyltetrazolium chloride-stained rat brains. Stroke 1996 Sep;27(9):1657-1662.
149. Djalali AG, Sadovnikoff N. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 2005 Mar;102(3):699-700; author reply 700.
150. Ricchiuti V, Sharkey SW, Murakami MM, Voss EM, Apple FS. Cardiac troponin I and T alterations in dog hearts with myocardial infarction: correlation with infarct size. Am J Clin Pathol 1998 Aug;110(2):241-247.
151. Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey J, et al. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol 2010 Nov;105(6):677-686.
152. Schott RJ, Rohmann S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 1990 Apr;66(4):1133-1142.
153. Topol EJ. Nesiritide-not verified. N Engl J Med 2005 Jul 14;353(2):113-116.
154. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011 Jul 7;365(1):32-43.
155. Pleister AP, Baliga RR, Haas GJ. Acute study of clinical effectiveness of nesiritide in decompensated heart failure: nesiritide redux. Curr Heart Fail Rep 2011 Sep;8(3):226-232.
156. Gwon HC, Jeong JO, Kim HJ, Park SW, Lee SH, Park SJ, et al. The feasibility and safety of fluoroscopy-guided percutaneous intramyocardial gene injection in porcine heart. Int J Cardiol 2001 Jun;79(1):77-88.
157. Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ, et al. Number of Coronary Heart Disease Risk Factors and Mortality in Patients With First Myocardial Infarction. JAMA 2011 Nov 16;306(19):2120-2127.